Adoption of QVAR on pediatrics clinical services
Project Description: Beclomethasone dipropionate HFA (QVAR) is an emergent alternative to fluticasone propionate HFA (flovent) for the treatment of asthma. Research provides evidence of comparative effectiveness and safety. QVAR was recently added to the UFHealth formulary and is now able to be prescribed by providers. The purpose of this project is to track the adoption of QVAR in pediatric patients admitted for asthma after May 1, 2017.
QPI: Erik, Black, (email@example.com)
UF Health Big Aims: Reduce Variation None
MeSH Keywords: Fluticasone, Asthma, Beclomethasone, Inpatients, Pediatrics